Intrathecal therapy for chronic pain: Current trends and future needs

Current Pain and Headache Reports

Volumn 18, Issue 1, 2014, Pages

  Hayek, Salim M ^a,b   Hanes, Michael C ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Complications; Indications; Mechanism of action; Microdosing; Noncancer pain; Opioid tolerance; Trialing

Indexed keywords

BACLOFEN; BUPIVACAINE; CLONIDINE; FENTANYL; HYDROMORPHONE; MORPHINE; OMEGA CONOTOXIN MVIIA; LOCAL ANESTHETIC AGENT; NARCOTIC ANALGESIC AGENT;

ANALGESIA; CATHETER COMPLICATION; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID FLOW; CHRONIC PAIN; CONFUSION; CONSTIPATION; DEPRESSION; DIZZINESS; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FOOD AND DRUG ADMINISTRATION; GRANULOMA; HEMATOMA; HUMAN; HYPERALGESIA; HYPOGONADISM; INSOMNIA; INTRATHECAL DRUG DELIVERY SYSTEM; LIQUORRHEA; MEMORY DISORDER; MICRODOSING; NAUSEA; NEUROPATHIC PAIN; NEUROTOXICITY; NIGHTMARE; NOCICEPTIVE PAIN; NYSTAGMUS; PATIENT SELECTION; PERIPHERAL EDEMA; PERSONAL THERAPY MANAGER; POSTDURAL PUNCTURE HEADACHE; PRURITUS; RECOMMENDED DRUG DOSE; RESPIRATION DEPRESSION; REVIEW; SPINAL CORD INJURY; TREATMENT INDICATION; URINE RETENTION; WOUND DEHISCENCE; WOUND INFECTION; XEROSTOMIA; DRUG ADMINISTRATION; EVIDENCE BASED MEDICINE; FEMALE; INTRACTABLE PAIN; INTRASPINAL DRUG ADMINISTRATION; MALE; METHODOLOGY; NEEDS ASSESSMENT; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ANALGESICS, OPIOID; ANESTHETICS, LOCAL; DRUG ADMINISTRATION SCHEDULE; DRUG DELIVERY SYSTEMS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; INJECTIONS, SPINAL; MALE; NEEDS ASSESSMENT; PAIN, INTRACTABLE; TREATMENT OUTCOME;

EID: 84889819680     PISSN: 15313433     EISSN: 15343081     Source Type: Journal    
DOI: 10.1007/s11916-013-0388-x     Document Type: Review

References (84)

1. Bier A. Atempts over Cocainisirung of the Ruckenmarkers [in German]. Deutsche Zeitschrift für Chirurgie. 1899;51:9.
2. Kitagawa O. On spinal anesthesia with cocaine. Jpn Soc Surg. 1901;3:185-91.
3. Knight KH, Brand FM, McHaourab AS, Veneziano G. Implantable intrathecal pumps for chronic pain: highlights and updates. Croat Med J. 2007;48:22-34.
4. Yaksh TL, Wilson PR, Kaiko RF, Inturrisi CE. Analgesia produced by a spinal action of morphine and effects upon parturition in the rat. Anesthesiology. 1979;51:386-92. (Pubitemid 10198565)
5. Goldstein A, Lowney LI, Pal BK. Stereospecific and nonspecific interactions of the morphine congener levorphanol in subcellular fractions of mouse brain. Proc Natl Acad Sci U S A. 1971;68:1742-7.
6. Pert CB, Snyder SH. Opiate receptor: demonstration in nervous tissue. Science. 1973;179:1011-4.
7. Wang JK, Nauss LA, Thomas JE. Pain relief by intrathecally applied morphine in man. Anesthesiology. 1979;50:149-51. (Pubitemid 9130744)
8. Onofrio BM, Yaksh TL, Arnold PG. Continuous low-dose intrathecal morphine administration in the treatment of chronic pain of malignant origin. Mayo Clin Proc. 1981;56:516-20. (Pubitemid 11023593)
9. Coombs DW, Saunders RL, Gaylor MS, Block AR, Colton T, Harbaugh R, et al. Relief of continuous chronic pain by intraspinal narcotics infusion via an implanted reservoir. JAMA. 1983;250:2336-9. (Pubitemid 13019248)
10. Auld AW, Maki-Jokela A, Murdoch DM. Intraspinal narcotic analgesia in the treatment of chronic pain. Spine. 1985;10:777-81. (Pubitemid 16188061)
11. Paice JA, Penn RD, Shott S. Intraspinal morphine for chronic pain: a retrospective, multicenter study. J Pain Symptom Manage. 1996;11:71-80. (Pubitemid 26073492)
12. Penn RD, Paice JA. Chronic intrathecal morphine for intractable pain. J Neurosurg. 1987;67:182-6. doi:10.3171/jns.1987.67.2.0182. (Pubitemid 17102045)
13. Henry-Feugeas MC, Idy-Peretti I, Baledent O, Poncelet-Didon A, Zannoli G, Bittoun J, et al. Origin of subarachnoid cerebrospinal fluid pulsations: a phase-contrast MR analysis. Magn Reson Imaging. 2000;18:387-95. (Pubitemid 30228577)
14. Friese S, Hamhaber U, Erb M, Kueker W, Klose U. The influence of pulse and respiration on spinal cerebrospinal fluid pulsation. Invest Radiol. 2004;39:120-30. doi:10.1097/01.rli.0000112089.66448.bd. (Pubitemid 38140543)
15. Alperin N, Vikingstad EM, Gomez-Anson B, Levin DN. Hemodynamically independent analysis of cerebrospinal fluid and brain motion observed with dynamic phase contrast MRI. Magn Reson Med. 1996;35:741-54. (Pubitemid 26134570)
16. Stockman HW. Effect of anatomical fine structure on the flow of cerebropsinal fluid in the spinal subarachnoid space. J Biochem Eng. 2006;128:106-14.
17. Degrell I, Nagy E. Concentration gradients for HVA, 5-HIAA, ascorbic acid, and uric acid in cerebrospinal fluid. Biol Psychiatry. 1990;27:891-6. (Pubitemid 20145676)
18. Bernards CM. Cerebrospinal fluid and spinal cord distribution of baclofen and bupivacaine during slow intrathecal infusion in pigs. Anesthesiology. 2006;105:169-78. (Pubitemid 44305206)
19. • Hettiarachchi HD, Hsu Y, Harris Jr TJ, Penn R, Linninger AA, Hettiarachchi HD, et al. The effect of pulsatile flow on intrathecal drug delivery in the spinal canal. Ann Biomed Eng. 2011;39. A study that analyzed cerebrospinal fluid flow patterns using single photon emission computed tomography in a human spine model as a predictor for the deliveery patterns of intrathecal drugs.
20. Bernards CM. Understanding the physiology and pharmacology of epidural and intrathecal opioids. Best Pract Res Clin Anaesthesiol. 2002;16:489-505. (Pubitemid 38937099)
21. Ummenhofer WC, Arends RH, Shen DD, Bernards CM. Comparative spinal distribution and clearance kinetics of intrathecally administered morphine, fentanyl, alfentanil, and sufentanil. Anesthesiology. 2000;92:739-53. (Pubitemid 30130177)
22. McQuay HJ, Sullivan AF, Smallman K, Dickenson AH. Intrathecal opioids, potency and lipophilicity. Pain. 1989;36:111-5. (Pubitemid 19024973)
23. Hayek SM, Joseph PN, Mekhail NA. Pharmacology of intrathecally administered agents for treatment of spasticity and pain. Semin Pain Med. 2003;1:238-53. doi:10.1016/j.spmd.2004.02.002. (Pubitemid 40432856)
24. Herz AT H. Activities and sites of antinociceptive action of morphine-like analgesics and kinetics of distribution following intravenous, intracerebral and intraventricular application. In: Simmonds, editor. Advances in Drug Research. London: Academic Press; 1971. p. p. 739-53.
25. Bernards CM. Recent insights into the pharmacokinetics of spinal opioids and the relevance to opioid selection. Curr Opin Anaesthesiol. 2004;17:441-7. (Pubitemid 39331953)
26. •• Deer TR, Prager J, Levy R, Rathmell J, Buchser E, Burton A, et al. Polyanalgesic Consensus Conference 2012: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation. 2012;15:436-64. doi:10.1111/j.1525-1403.2012.00476.x. Recommendations on proper management of intrathecal drug delivery systems developed by an expert panel.
27. Coffey RJ, Owens ML, Broste SK, Dubois MY, Ferrante FM, Schultz DM, et al. Mortality associated with implantation and management of intrathecal opioid drug infusion systems to treat noncancer pain. Anesthesiology. 2009;111:881-91. doi:10.1097/ALN.0b013e3181b64ab8.
28. Coffey RJ, Owens ML, Broste SK, Dubois MY, Ferrante FM, Schultz DM, et al. Medical practice perspective: identification and mitigation of risk factors for mortality associated with intrathecal opioids for noncancer pain. Pain Med. 2010;11:1001-9. doi:10.1111/j.1526-4637.2010.00889.x.
29. .• Hayek SM, Veizi IE, Narouze SN, Mekhail N. Age-dependent intrathecal opioid escalation in chronic noncancer pain patients. Pain Med. 2011;12:1179-89. doi:10.1111/j.1526-4637.2011.01188.x.
30. Veizi IE, Hayek SM, Narouze S, Pope JE, Mekhail N. Combination of intrathecal opioids with bupivacaine attenuates opioid dose escalation in chronic noncancer pain patients. Pain Med. 2011;12:1481-9. doi:10.1111/j.1526- 4637.2011.01232.x.
31. Dominguez E, Sahinler B, Bassam D, Day M, Lou L, Racz G, et al. Predictive value of intrathecal narcotic trials for long-term therapy with implantable drug administration systems in chronic noncancer pain patients. Pain Pract. 2002;2:315-25. doi:10.1046/j.1533-2500.2002.02040.x.
32. Grider JSH, Etscheidt MA. Patient selection and outcomes using a low-dose intrathecal opioid trialing method for chronic nonmalignant pain. Pain Physician. 2011;14:343-51.
33. • Hamza M, Doleys D, Wells M, Weisbein J, Hoff J, Martin M. A prospective study evaluating the efficacy of opioid cessation and the use of low-dose intrathecal opioid management of noncancer pain.
34. Deer T, Krames ES, Hassenbusch S, Burton A, Caraway D, Dupen S, et al. Management of Intrathecal Catheter-Tip Inflammatory Masses: an updated 2007 consensus statement froman expert panel. Neuromodulation. 2008;11:77-91. doi:10.1111/j.1525-1403.2008.00147.x. (Pubitemid 351490209)
35. Allen JW, Horais KA, Tozier NA, Wegner K, Corbeil JA, Mattrey RF, et al. Time course and role of morphine dose and concentration in intrathecal granuloma formation in dogs: a combined magnetic resonance imaging and histopathology investigation. Anesthesiology. 2006;105:581-9. (Pubitemid 44310443)
36. Deer TR, Prager J, Levy R, Rathmell J, Buchser E, Burton A, et al. Polyanalgesic Consensus Conference - 2012: consensus on diagnosis, detection, and treatment of catheter-tip granulomas (inflammatory masses). Neuromodulation. 2012;15:483-95. doi:10.1111/j.1525-1403.2012.00449.x. discussion 96.
37. Tomycz ND, Ortiz V, McFadden KA, Urgo L, Moossy JJ. Management of symptomatic intrathecal catheter-associated inflammatory masses. Clin Neurol Neurosurg. 2012;114:190-5.
38. Boswell MV, Iacono RP, Guthkelch AN. Sites of action of subarachnoid lidocaine and tetracaine: observations with evoked potential monitoring during spinal cord stimulator implantation. Reg Anesth. 1992;17:37-42.
39. Tejwani GA, Rattan AK, McDonald JS. Role of spinal opioid receptors in the antinociceptive interactions between intrathecal morphine and bupivacaine. Anesth Analg. 1992;74:726-34.
40. Penning JP, Yaksh TL. Interaction of intrathecal morphine with bupivacaine and lidocaine in the rat. Anesthesiology. 1992;77:1186-2000.
41. Ortner CM, Posch M, Roessler B, Faybik P, Rutzler K, Grabovica J, et al. On the ropivacaine-reducing effect of low-dose sufentanil in intrathecal labor analgesia. Acta Anaesthesiol Scand. 2010;54:1000-6. doi:10.1111/j.1399-6576. 2010.02254.x.
42. Parpaglioni R, Baldassini B, Barbati G, Celleno D. Adding sufentanil to levobupivacaine or ropivacaine intrathecal anaesthesia affects the minimum local anaesthetic dose required. Acta Anaesthesiol Scand. 2009;53:1214-20. doi:10.1111/j.1399-6576.2009.02033.x.
43. Levin A, Datta S, Camann WR. Intrathecal ropivacaine for labor analgesia: a comparison with bupivacaine. Anesth Analg. 1998;87:624-7. (Pubitemid 28397487)
44. van Dongen RT, Crul BJ, van Egmond J. Intrathecal coadministration of bupivacaine diminishes morphine dose progression during long-term intrathecal infusion in cancer patients. Clin J Pain. 1999;15:166-72. (Pubitemid 29467546)
45. Mironer YE, Haasis JC, Chapple I, Brown C, Satterthwaite JR. Efficacy and safety of intrathecal opioids/bupivacaine mixture in chronic nonmalignant pain: a double blind, randomized, crossover, multicenter study by the National Forum of Independent Pain Clinicians (NFIPC). Neuromodulation. 2002;5:208-13. (Pubitemid 36083992)
46. Zhong Z, Qulian G, Yuan Z, Wangyuan Z, Zhihua S. Repeated intrathecal administration of ropivacaine causes neurotoxicity in rats. Anaesth Intensive Care. 2009;37:929-36.
47. Malinovsky JM, Charles F, Baudrimont M, Pereon Y, Le Corre P, Pinaud M, et al. Intrathecal ropivacaine in rabbits: pharmacodynamic and neurotoxicologic study. Anesthesiology. 2002;97:429-35. (Pubitemid 34847757)
48. Yamashita A, Matsumoto M, Matsumoto S, Itoh M, Kawai K, Sakabe T. A comparison of the neurotoxic effects on the spinal cord of tetracaine, lidocaine, bupivacaine, and ropivacaine administered intrathecally in rabbits. Anesth Analg. 2003;97:512-9. table of contents. (Pubitemid 36899758)
49. Sjoberg M, Nitescu P, Appelgren L, Curelaru I. Long-term intrathecal morphine and bupivacaine in patients with refractory cancer pain. Results from a morphine:bupivacaine dose regimen of 0.5: 4.75 mg/mL. Anesthesiology. 1994;80:284-97. (Pubitemid 24064031)
50. Nitescu P, Dahm P, Appelgren L, Curelaru I. Continuous infusion of opioid and bupivacaine by externalized intrathecal catheters in long-term treatment of "refractory" nonmalignant pain. Clin J Pain. 1998;14:17-28. (Pubitemid 28146045)
51. McGivern JG. Ziconotide: a review of its pharmacology and use in the treatment of pain. Neuropsychiatr Dis Treat. 2007;3:69-85. (Pubitemid 46779923)
52. Wermeling D, Drass M, Ellis D, Mayo M, McGuire D, O'Connell D, et al. Pharmacokinetics and pharmacodynamics of intrathecal ziconotide in chronic pain patients. J Clin Pharmacol. 2003;43:624-36. (Pubitemid 36613121)
53. Staats PS, Yearwood T, Charapata SG, Presley RW, Wallace MS, Byas-Smith M, et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA. 2004;291:63-70. doi:10.1001/jama.291.1.63. (Pubitemid 38040536)
54. Wallace MS, Charapata SG, Fisher R, Byas-Smith M, Staats PS, Mayo M, et al. Intrathecal ziconotide in the treatment of chronic nonmalignant pain: a randomized, double-blind, placebo-controlled clinical trial. Neuromodulation. 2006;9:75-86. doi:10.1111/j.1525-1403.2006.00055.x.
55. Rauck RL, Wallace MS, Leong MS, Minehart M, Webster LR, Charapata SG, et al. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. J Pain Symptom Manage. 2006;31:393-406. doi:10.1016/j.jpainsymman.2005.10.003.
56. Wallace MS, Rauck R, Fisher R, Charapata SG, Ellis D, Dissanayake S. Intrathecal ziconotide for severe chronic pain: safety and tolerability results of an open-label, long-term trial. Anesth Analg. 2008;106:628-37. doi:10.1213/ane.0b013e3181606fad. (Pubitemid 351156693)
57. Maier C, Gockel HH, Gruhn K, Krumova EK, Edel MA. Increased risk of suicide under intrathecal ziconotide treatment? - a warning. Pain. 2011;152:235-7. doi:10.1016/j.pain.2010.10.007.
58. Feng X, Zhang F, Dong R, Li W, Liu J, Zhao X, et al. Intrathecal administration of clonidine attenuates spinal neuroimmune activation in a rat model of neuropathic pain with existing hyperalgesia. Eur J Pharmacol. 2009;614:38-43. doi:10.1016/j.ejphar.2009.04.044.
59. Yaksh TL, Rathbun M, Jage J, Mirzai T, Grafe M, Hiles RA. Pharacology and toxicology of chronically infused epidural clonidine.HCl in dogs. Fundam Appl Toxicol. 1994;23:319-35. (Pubitemid 24321716)
60. Yaksh TL, Horais KA, Tozier NA, Allen JW, Rathbun M, Rossi SS, et al. Chronically infused intrathecal morphine in dogs. Anesthesiology. 2003;99:174-87. (Pubitemid 36799049)
61. Bevacqua BK, Fattouh M, Backonja M. Depression, night terrors, and insomnia associated with long-term intrathecal clonidine therapy. Pain Pract. 2007;7:36-8. doi:10.1111/j.1533-2500.2007.00108.x.
62. Belverud S, Mogilner A, Schulder M. Intrathecal pumps. Neurotherapeutics. 2008;5:114-22. doi:10.1016/j.nurt.2007.10.070. (Pubitemid 350299303)
63. Gerber HR. Intrathecal morphine for chronic benign pain. Best Pract Res Clin Anaesthesiol. 2003;17:429-42. (Pubitemid 38950006)
64. Turner JA, Sears JM, Loeser JD. Programmable intrathecal opioid delivery systems for chronic noncancer pain: a systematic review of effectiveness and complications. Clin J Pain. 2007;23:180-95. doi:10.1097/01.ajp.0000210955.93878. 44. (Pubitemid 46145465)
65. Brown J, Klapow J, Doleys D, Lowery D, Tutak U. Disease-specific and generic health outcomes: a model for the evaluation of long-term intrathecal opioid therapy in noncancer low back pain patients. Clin J Pain. 1999;15:122-31. (Pubitemid 29265945)
66. Cleeland CS, Gonin R, Hatfield AK, Edmonson JH, Blum RH, Stewart JA, et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med. 1994;330:592-6. doi:10.1056/NEJM199403033300902. (Pubitemid 24065792)
67. Rauck RL, Cherry D, Boyer MF, Kosek P, Dunn J, Alo K. Long-term intrathecal opioid therapy with a patient-activated, implanted delivery system for the treatment of refractory cancer pain. J Pain. 2003;4:441-7. (Pubitemid 37310649)
68. Smith TJ, Staats PS, Deer T, Stearns LJ, Rauck RL, Boortz-Marx RL, et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain, drug related toxicitiy, and survival. J Clin Oncol. 2002;20:4040-9.
69. Smith TJ, Coyne PJ, Staats PS, Deer T, Stearns LJ, Rauck RL, et al. An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM). Ann Oncol. 2005;16:825-33. doi:10.1093/annonc/mdi156. (Pubitemid 40767106)
70. Burton AW, Rajagopal A, Shah HN, Mendoza T, Cleeland C, Hassenbusch SJ, et al. Epidural and intrathecal analgesia is effective in treating refractory cancer pain. Pain Med. 2004;5:239-47. doi:10.1111/J.1526-4637.2004.04037.X. (Pubitemid 39369243)
71. Ahmed SU, Martin NM, Chang Y. Patient selection and trial methods for intraspinal drug delivery for chronic pain: a national survey. Neuromodulation. 2005;8:112- 20. doi:10.1111/j.1525-1403.2005.00227.x.
72. Anderson VC, Burchiel KJ, Cooke B. A Prospective, randomized trial of intrathecal injection vs. epidural infusion in the selection of patients for continuous intrathecal opioid therapy. Neuromodulation. 2003;6:142-52. (Pubitemid 36897466)
73. Kim D, Saidov A, Mandhare V, Shuster A. Role of pretrial systemic opioid requirements, intrathecal trial dose, and nonpsychological factors as predictors of outcome for intrathecal pump therapy: one clinician's experience with lumbar postlaminectomy pain. Neuromodulation. 2011;14:165-75.
74. Kamran S, Wright BD. Complications of intrathecal drug delivery systems. Neuromodulation. 2001;4:111-5. doi:10.1046/j.1525-1403.2001.00111.x. (Pubitemid 32645984)
75. Follett KA, Naumann CP. A prospective study of catheter-related complications of intrathecal drug delivery systems. J Pain Symptom Manage. 2000;19:209-15. (Pubitemid 30173235)
76. Follett KA, Burchiel K, Deer T, Dupen S, Prager J, Turner MS, et al. Prevention of intrathecal drug delivery catheter-related complications. Neuromodulation. 2003;6:32-41. doi:10.1046/j.1525-1403.2003.03005.x. (Pubitemid 36667610)
77. Deer TR, Prager J, Levy R, Burton A, Buchser E, Caraway D, et al. Polyanalgesic Consensus Conference - 2012: recommendations on trialing for intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation. 2012;15:420-35. doi:10.1111/j.1525-1403.2012.00450.x. discussion 35.
78. Peerdeman SM, de Groot V, Feller RE. In situ treatment of an infected intrathecal baclofen pump implant with gentamicin-impregnated collagen fleece. J Neurosurg. 2010;112:1308-10. doi:10.3171/2009.8.JNS081692.
79. Diefenbeck M, Muckley T, Hofmann GO. Prophylaxis and treatment of implant-related infections by local application of antibiotics. Injury. 2006;37 Suppl 2:S95-104. doi:10.1016/j.injury.2006.04.015.
80. Ilias W, le Polain B, Buchser E, Demartini L; oPTIMa study group. Patient-controlled analgesia in chronic pain patients: experience with a new device designed to be used with implanted programmable pumps. Pain Pract. 2008;8:164-70. (Pubitemid 351663358)
81. Maeyaert J, Buchser E, Van Buyten JP, Rainov NG, Becker R. Patient-controlled analgesia in intrathecal therapy for chronic pain: safety and effective operation of the Model 8831 Personal Therapy Manager with a Pre-implanted SynchroMed Infusion System. Neuromodulation. 2003;6:133-41. doi:10.1046/j.1525-1403.2003.03021.x. (Pubitemid 36897465)
82. Hayek SM. Intrathecal "microdosing": reality or artifact? Pain Med. 2012;13:1664-5. doi:10.1111/j.1526-4637.2012.01507.
83. Brodner RA, Taub A. Chronic pain exacerbated by long-term narcotic use in patients with nonmalignant disease: clinical syndrome and treatment. Mt Sinai J Med. 1978;45:233-7. (Pubitemid 8362490)
84. Taylor CB, Zlutnick SI, Corley MJ, Flora J. The effects of detoxification, relaxation, and brief supportive therapy on chronic pain. Pain. 1980;8:319-29. (Pubitemid 10071335)